Valneva's Lyme Data Land With a Thud as Goldman Trims Its Enthusiasm to a Nudge
Published on 10/29/2026 at 14:31 | Editorial boerse-global.de
Goldman Sachs nudged its price target on Valneva higher yesterday, from €2.15 to €2.20, yet left its sell recommendation untouched. The distinction matters more than the two-cent adjustment: a firmer number is not a warmer verdict. Shares added 3.0% in the session, and media reports linked the rebound to the target change, but the stock closed at €2.53 — comfortably above the newly raised objective. Read plainly, the analysts are still signalling caution, not upside from here.
A small revision, not a change of heart
Anyone treating the upgrade as a buying case would be granting it more weight than the unchanged sell rating can bear. No re-rating in the company's favour follows from it. The market's friendly reaction and the brokerage's skeptical stance are two separate facts, and they should be kept apart.
Behind the caution sits the readout for LB6V, the Lyme disease vaccine candidate developed with Pfizer. Presented on 21 October at IDWeek, the Phase 3 VALOR trial showed 73.2% efficacy measured 28 days after the fourth dose. That is a genuinely positive number. It is also not the whole story.
Efficacy met, statistics missed
The primary endpoint was missed. What tripped the analysis was not the measured protection but the statistical certainty behind it. The lower bound of the 95% confidence interval came in at 15.8%, against a pre-specified floor of 20%. The interval itself stretched from 15.8% to 93.5% — a spread that says as much about the strength of the evidence as the headline figure does.
Should investors sell immediately? Or is it worth buying Valneva?
So the result cannot be filed under either "effective" or "ineffective." VALOR delivered a positive efficacy estimate while falling short of the statistical bar set in advance. A reading that leans only on the 73.2% would bury the decisive caveat; one that dismisses the shot outright would ignore a real signal. Both statements — a working vaccine estimate and a failed primary analysis — can hold at the same time.
London closes the door on IXCHIQ
A separate thread concerns IXCHIQ, Valneva's chikungunya vaccine. On 20 October, Britain's MHRA withdrew its UK marketing authorisation after a safety review concluded the benefit-risk balance was no longer favourable. The regulator pointed to serious side effects, including rare neurological events.
Valneva's response was that the decision was not tied to any newly identified safety signal and that approvals elsewhere remain unaffected. That caveat belongs in the picture: the British move is not a verdict on every market where the shot is sold.
Valneva at a turning point? This analysis reveals what investors need to know now.
Two risks, two ledgers
For investors, the two developments sit on different planes. LB6V is a question of how much weight clinical evidence can carry and where a statistical threshold was missed. IXCHIQ is a regulatory call following a safety assessment. Sound judgment on Valneva requires holding them apart. A positive efficacy figure does not erase the shortfall in VALOR's primary analysis, and a UK withdrawal must not be inflated into a global one. In each case, what counts is the specific finding — and the limits of where it applies.
Ad
Valneva Stock: New Analysis - 29 October
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
